(Q53536522)

15 May 2018

title

Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer. (English)

1 reference

15 May 2018

1 reference

1 reference

Ruifang Sun

1

1 reference

15 May 2018

Zhigang Liu

2

1 reference

15 May 2018

Lumin Wang

3

1 reference

15 May 2018

Weidong Lv

4

1 reference

15 May 2018

Jia Liu

5

1 reference

15 May 2018

Caixia Ding

6

1 reference

15 May 2018

Yong Yuan

7

1 reference

15 May 2018

Guangyan Lei

8

1 reference

15 May 2018

Changfu Xu

9

1 reference

15 May 2018

publication date

18 April 2015

1 reference

15 May 2018

published in

Tumor Biology

1 reference

15 May 2018

volume

36

1 reference

15 May 2018

issue

9

1 reference

15 May 2018

page(s)

7195-7204

1 reference

15 May 2018

https://scigraph.springernature.com/pub.10.1007/s13277-015-3361-y

exact match

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Usefulness of the Palliative Prognostic Index in patients with lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Results of platinum-based chemotherapy in unselected performance status (PS) 2 patients with advanced non-small cell lung cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

The tubulin code: molecular components, readout mechanisms, and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

STMN-1 gene: a predictor of survival in stage iia esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Stathmin: a protein with many tasks. New biomarker and potential target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Stathmin 1: a novel therapeutic target for anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3361-Y

Response rate as an endpoint in clinical trials

21 January 2018

1 reference

12 December 2020

Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer

1 reference

12 December 2020

Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas

1 reference

12 December 2020

Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.

1 reference

12 December 2020

Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial

1 reference

12 December 2020

10.1007/S13277-015-3361-Y

Identifiers

DOI

1 reference

15 May 2018

release_5jhi7xu6qjgrhjvjv37lqnbvly

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5jhi7xu6qjgrhjvjv37lqnbvly

24 November 2022

mapped directly with Wikidata item

1 reference

15 May 2018